SQZ Biotech, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SQZ Biotech, Inc. - overview
Established
2013
Location
Watertown, MA, US
Primary Industry
Biotechnology
About
SQZ Biotech, Inc. is a US-based company specializing in innovative cell therapy platforms that create targeted therapies for various diseases, particularly cancer and autoimmune conditions. Founded in 2013 and headquartered in Watertown, US, SQZ Biotech, Inc. focuses on developing cell therapies that leverage cellular properties to treat diseases.
The company has engaged in 11 deals, with its most recent funding round occurring on October 29, 2020, when it raised USD 2. 00 mn in a Grant from The National Institutes of Health as part of its total amount raised of USD 60. 00 mn. The company’s CEO and founder, Armon Sharei, has a history of leadership in biotechnology ventures.
SQZ Biotech develops cell-based therapies utilizing proprietary technology to enhance the immune response against tumors while minimizing harm to healthy tissue. They primarily cater to biotechnology and pharmaceutical companies, providing advanced cell therapies for integration into their product pipelines and conducting business in North America and Europe. In 2022, SQZ Biotech generated a revenue of USD 21. 48 mn, with an EBITDA loss of USD 69.
00 mn, highlighting the company's focus on long-term growth in the biotech sector through strategic collaborations and partnerships. SQZ Biotech plans to enhance its multi-functional cell therapy pipeline through recent funding. Notably, the company raised USD 60. 00 mn in February 2021, intending to utilize these funds for the development of upcoming product offerings.
The company is also targeting expansion into additional geographic regions, with a focus on markets in Europe and Asia by 2024.
Current Investors
Polaris Partners, +ND Capital, GV
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.sqzbiotech.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.